文献速递骨显像与常规 SPECT肿瘤 PET/CT

68Ga-DOTA-FAPI-04与18F-FDG PET/CT在SAPHO综合征患者中的比较

Comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/CT in Patients With SAPHO Syndrome.
PubMed 文献 · Clin Nucl Med · 2023-05-26

对21例已知SAPHO综合征患者连续两天行68Ga-DOTA-FAPI-04与18F-FDG PET/CT,共检出38处受累部位,68Ga-DOTA-FAPI-04检出全部18F-FDG所示病灶并额外检出10处,骨受累摄取及靶本比显著更高,与当前骨关节症状一致性为κ=0.79。

要点

  • 68Ga-DOTA-FAPI-04 PET/CT检出全部18F-FDG所示病灶并额外检出10处病灶。
  • 骨受累中68Ga-DOTA-FAPI-04的摄取和靶本比显著高于18F-FDG。
  • 68Ga-DOTA-FAPI-04阳性病灶与当前骨关节病变一致性为κ=0.79(P<0.001)。

核心结论

  • 68Ga-DOTA-FAPI-04有潜力作为评估SAPHO综合征的有前景的显像剂。

研究设计与样本

  • 对21例已知SAPHO综合征患者行68Ga-DOTA-FAPI-04 PET/CT,所有患者连续2天分别接受68Ga-DOTA-FAPI-04与18F-FDG PET/CT。

主要发现

  • 共检出38处受累部位,18F-FDG PET/CT显示28处病灶,68Ga-DOTA-FAPI-04 PET/CT检出18F-FDG所示全部病灶并额外检出10处病灶。
  • 骨受累中68Ga-DOTA-FAPI-04扫描的摄取和靶本比显著高于18F-FDG。
  • 68Ga-DOTA-FAPI-04阳性病灶与当前骨关节病变一致性为κ=0.79(P<0.001),18F-FDG与临床症状一致性为κ=0.52(P<0.001)。

关键数值与推荐

  • 68Ga-DOTA-FAPI-04阳性病灶与当前骨关节病变一致性κ=0.79(P<0.001),为高度一致。
  • 18F-FDG与临床症状一致性κ=0.52(P<0.001),为低至中度一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PATIENTS AND METHODS: 68Ga-DOTA-FAPI-04 PET/CT was performed on a cohort of 21 patients with known SAPHO syndrome. All patients underwent 68Ga-DOTA-FAPI-04 and 18F-FDG PET/CT on 2 consecutive days. The positive rates of the PET/CT scans at the sites of the osteoarticular symptom, the uptake values, and agreement with clinical osteoarticular symptom were compared. RESULTS: A total of 38 sites of involvement were detected. 18F-FDG PET/CT revealed 28 lesions. In contrast, 68Ga-DOTA-FAPI-04 PET/CT detected not only all lesions shown on 18F-FDG PET/CT but additional 10 lesions. 68Ga-DOTA-FAPI-04 scan also demonstrated significantly higher uptake and target-to-background ratio than 18F-FDG studies in the skeletal involvements. The agreement between 68Ga-DOTA-FAPI-04-positive lesions and current osteoarticular lesions was substantial (κ = 0.79, P < 0.001), whereas 18F-FDG had low to moderate agreement with clinical symptoms (κ = 0.52, P < 0.001). CONCLUSIONS: 68Ga-DOTA-FAPI-04 has potential as a promising imaging agent for the evaluation of SAPHO syndrome.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang P, Li C, Hou G, et al. Comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/CT in Patients With SAPHO Syndrome. Clin Nucl Med. 2023. PMID: 37543757. doi:10.1097/RLU.0000000000004724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。